TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04090528

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pTVG-HP
Description: pTVG-HP is a plasmid DNA, produced in E. coli, that encodes the complementary deoxyribonucleic acid (cDNA) for human prostatic acid phosphatase (PAP).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pTVG-HP
Description: pTVG-HP is a plasmid DNA, produced in E. coli, that encodes the complementary deoxyribonucleic acid (cDNA) for human prostatic acid phosphatase (PAP).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pTVG-AR
Description: pTVG-AR is a plasmid DNA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with multiple different types of cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with multiple different types of cancer.
Study: NCT03372733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: control olive oil (COO)
Description: 2 capsules, 2 times a day after meals in a total of 4 capsules a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palmitoleate-rich oil (PLO)
Description: 2 capsules, 2 times a day after meals in a total of 4 capsules a day
Study: NCT02347995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein
Description: This training is designed to target the major muscle groups of the leg. Resistance training will be completed through a combination of lower extremity machines and complemented by whole body exercises such as squatting. The lower extremity machines include leg press, leg extension, and leg curl. This group will drink a beverage containing protein after each training session.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This training is designed to target the major muscle groups of the leg. Resistance training will be completed through a combination of lower extremity machines and complemented by whole body exercises such as squatting. The lower extremity machines include leg press, leg extension, and leg curl.This group will drink a placebo beverage after each training session.
Study: NCT02602496

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: 3 servings of refined grain
Study: NCT03639298

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intendu
Description: intensive training with Motion Based Cognitive Video Games Software
Study: NCT01660698

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: maltodextrin powder

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: probiotic blended in maltodextrin powder
Study: NCT01053221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolic Acid
Description: Mycophenolate mofetil: 750mg po bid x 36 months OR mycophenolate sodium 540mg po bid x 36 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care: CNI and MPA
Description: Tacrolimus or cyclosporine: dosed according to trough levels per standard of care Mycophenolate mofetil 750mg po bid or mycophenolate sodium 540mg po bid x 36 months
Study: NCT02246660

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Description: The dose of Resveratrol will be 500 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative.~OR~The dose of Resveratrol will be 125 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Description: The dose of Resveratrol will be 500 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative.~OR~The dose of Resveratrol will be 125 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be taken orally for 6 months.
Study: NCT03018704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: anticonvulsant medication. The medication was dosed twice per day with a starting dose of 25 mg, increasing the dose as tolerated to 200mg daily in divided doses. Patient were titrated to the highest dose tolerable.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: inactive medication. the doses of placebo were titrated the same as the active intervention.
Study: NCT02397785

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ApexM
Description: Subjects will apply conductive gel, insert the device to a minimum depth of 4 inches, and inflate until comfortably snug. The intensity is set exclusively by the physician to a tolerated sensory level, avoiding muscle contraction. At the target amplitude, patients will feel a non-painful fluttering or tapping sensation, Subjects will perform this for 6 sessions per week at 12 minutes per session for an additional 12 weeks. At each follow-up visit, investigators will re-evaluate the stimulation level and adjust to avoid muscle contraction.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: Identical to ApexM but will not deliver any electrical stimulation
Study: NCT01110434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Topiramate (200 mg daily)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (daily)
Study: NCT03957720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMPS
Description: Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMPS
Description: Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMPS
Description: Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMPS
Description: Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMPS
Description: Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penicillamine
Description: Dosage Form: Penicillamine: 250-1500mg per day, Frequency:TID,Duration: 5 years;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMSA
Description: Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMSA
Description: Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;
Study: NCT00359606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluoro-2-Deoxycytidine (FdCyd)
Description: Given PO and IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative Studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative Studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrouridine (THU)
Description: Given PO and IV
Study: NCT02915315

Intervention type: DIETARY_SUPPLEMENT
Intervention: salt
Description: The protocol comprise a questionnaire survey and physical examination during a 3-day baseline observation period, a low-salt diet for 7 days (3g of salt per day) and a high-salt diet for 7 days (18g of salt per day). During the baseline period, each subject is given detailed dietary instructions to avoid table salt, cooking salt, and high-salt foods for the 17-day study duration. To ensure compliance of study participants with the intervention program, they are required to have their breakfast, lunch, and dinner at the study kitchen under supervision of the study staff during the entire study period. All foods are cooked without salt. Onsite study staff members add repackaged salt to the meals of individual subjects as indicated by the study protocol.

Intervention type: DIETARY_SUPPLEMENT
Intervention: salt
Description: The protocol comprise a questionnaire survey and physical examination during a 3-day baseline observation period, a low-salt diet for 7 days (3g of salt per day) and a high-salt diet for 7 days (18g of salt per day). During the baseline period, each subject is given detailed dietary instructions to avoid table salt, cooking salt, and high-salt foods for the 17-day study duration. To ensure compliance of study participants with the intervention program, they are required to have their breakfast, lunch, and dinner at the study kitchen under supervision of the study staff during the entire study period. All foods are cooked without salt. Onsite study staff members add repackaged salt to the meals of individual subjects as indicated by the study protocol.
Study: NCT00175812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: all-trans retinoic acid (ATRA)
Description: All-trans retinoic acid 22.5 mg/square meter twice daily days 1-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic acid
Description: Valproic acid, highest dose without side effects from day 3 until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophyllin
Description: Theophyllin, targetted serum level 50-100 from day 3 until progression
Study: NCT02285270

Intervention type: DEVICE
Group type: OTHER
Intervention: FDG PET/CT
Description: PET/CT is a hybrid imaging modality that allows imaging positron emitting isotopes such as F-18 along with anatomic imaging using x-rays. The physiologic information from the PET component is co-registered with the anatomic information from the CT component, permitting accurate localization and quantification of physiologic processes. The most common clinically used positron emitting radiopharmaceutical is F-18 fluorodeoxyglucose (FDG). It is a glucose analog which is taken up by glucose transporters and phosphorylated to FDG-6P by hexokinase. FDG PET/CT gives a map of relative amount of glucose uptake and phosphorylation over the interval from injection to scan.
Study: NCT02866942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of Live attenuated influenza vaccine (LAIV)
Study: NCT06389890

Intervention type: PROCEDURE
Intervention: Pancreatic resection procedure
Description: Pancreatic resection procedure

Intervention type: PROCEDURE
Intervention: Pancreatic resection procedure
Description: Pancreatic resection procedure

Intervention type: PROCEDURE
Intervention: Pancreatic resection procedure
Description: Pancreatic resection procedure

Intervention type: PROCEDURE
Intervention: Pancreatic resection procedure
Description: Pancreatic resection procedure

Intervention type: PROCEDURE
Intervention: Pancreatic resection procedure
Description: Pancreatic resection procedure

Intervention type: PROCEDURE
Intervention: Pancreatic resection procedure
Description: Pancreatic resection procedure
Study: NCT02458924

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Niacin skin test
Description: Two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate were applied for one minute to the inside of the different forearms of each individual.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Niacin skin test
Description: Two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate were applied for one minute to the inside of the different forearms of each individual.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Niacin skin test
Description: Two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate were applied for one minute to the inside of the different forearms of each individual.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Niacin skin test
Description: Two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate were applied for one minute to the inside of the different forearms of each individual.
Study: NCT03513692

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fill-Up composite resin
Description: 2 arm study comparing restoration of a tooth with either FillUp composite or conventional composite

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fill-Up composite resin
Description: 2 arm study comparing restoration of a tooth with either FillUp composite or conventional composite
Study: NCT03801148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg dexlansoprazole capsules manufactured at TOB
Description: Dexlansoprazole delayed-release capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg dexlansoprazole capsules manufactured at TOB
Description: Dexlansoprazole delayed-release capsules.
Study: NCT04666558

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise & Nutrition
Description: App-based live group exercise classes, personalized follow-up asynchronous workouts, live group nutrition classes, and protein tracking.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise & Nutrition
Description: App-based live group exercise classes, personalized follow-up asynchronous workouts, live group nutrition classes, and protein tracking. Additional one-one-one exercise and nutrition support is provided too.
Study: NCT00586040

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tissue bonding
Description: application of rose bengal and treatment with green light

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sutures
Description: interrupted superficial sutures
Study: NCT00898638

Intervention type: OTHER
Intervention: biologic sample preservation procedure
Study: NCT01049204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maraviroc
Description: Maraviroc 150 mg twice daily for 24 weeks
Study: NCT00898638

Intervention type: OTHER
Intervention: biologic sample preservation procedure

Intervention type: OTHER
Intervention: medical chart review
Study: NCT01449812

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix+Hib™
Description: Intramuscular, one dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix+Hib™
Description: Intramuscular, one dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix+Hib™
Description: Intramuscular, one dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Poliorix™
Description: Intramuscular, one dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Poliorix™
Description: Intramuscular, one dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Poliorix™
Description: Intramuscular, one dose
Study: NCT04622319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8201a
Description: Administered initially as an intravenous (IV) infusion at a dose of 5.4 mg/kg on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: T-DM1
Description: Administered initially as an intravenous (IV) infusion at a dose of 3.6 mg/kg on Day 1 of each 21-day cycle
Study: NCT04568902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H3B-6545
Description: H3B-6545 oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H3B-6545
Description: H3B-6545 oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H3B-6545
Description: H3B-6545 oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H3B-6545
Description: H3B-6545 oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihistamine
Description: Systemic antihistamine oral drug such as fexofenadine, loratadine and cetirizine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihistamine
Description: Systemic antihistamine oral drug such as fexofenadine, loratadine and cetirizine.
Study: NCT04310007

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO
Study: NCT01049204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maraviroc
Description: Maraviroc 150 mg twice daily for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo twice daily for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo twice daily for 24 weeks
Study: NCT05066152

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (ATCC 53103)
Description: One probiotic drop contained a formulation of 1x109 Cfu Lactobacillus rhamnosus GG (LGG; ATCC 53103)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Carrier material of probiotic product, not containing bacterial strain, similar appearance as the probiotic
Study: NCT03490292

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Avelumab combined with Chemoradiation
Description: Co-administration of avelumab with chemoradiation in pre-operative period.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Avelumab combined with Chemoradiation
Description: Co-administration of avelumab with chemoradiation in pre-operative period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Weekly Carboplatin (AUC2) \[intravenous infusion on days 1, 8, 15, 22, \& 29\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Weekly Carboplatin (AUC2) \[intravenous infusion on days 1, 8, 15, 22, \& 29\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Weekly paclitaxel \[intravenous infusion on days 1, 8, 15, 22, \& 29\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Weekly paclitaxel \[intravenous infusion on days 1, 8, 15, 22, \& 29\]

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation therapy \[23 fractions, M-F, estimated completion day 35\]

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation therapy \[23 fractions, M-F, estimated completion day 35\]
Study: NCT03101488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN035
Description: KN035 is a monoclonal antibody drug which is formulated for subcutaneous injection in a single-use vial (brown neutral borosilicate) containing a total of 300 mg antibody in 1.5 ml of solution.
Study: NCT03892057

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based Positive Psychological Intervention
Description: The investigator's culturally-tailored internet-based Positive Psychology Intervention is a non-pharmacotherapy approach aimed at increasing positive emotional experiences by teaching individuals to engage in intentional activities known to increase psychological and emotional well- being, e.g., mindfulness/meditation. The current 5-week Internet-based intervention will be delivered via a secure website which participants will access at home (or in a public setting with Wi-Fi) using an assigned username and password. The on-line program includes didactic material and home practice with participants logging into the website 3-4 times per week for 15 to 20 minute sessions. In addition to weekly on-line instruction, participants are assigned homework as a means of incorporating skills learned into their day-to-day activities.
Study: NCT00142168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-5103 (lenalidomide)
Description: Taken orally once a day for 21 days followed by 7 days of no CC-5103 (lenalidomide)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Begins on week 2 of treatment and is given intravenously once a week for 4 weeks
Study: NCT01058915

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 5mg
Description: Rosuvastatin 5mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 40mg
Description: Rosuvastatin 40mg/day
Study: NCT02336685

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulranumab 1 mg
Description: Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulranumab 3 mg
Description: Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid
Description: Opioids will be administered as standard of care for osteoarthritis (OA) pain therapy during the double-blind treatment phase as per investigator discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid
Description: Opioids will be administered as standard of care for osteoarthritis (OA) pain therapy during the double-blind treatment phase as per investigator discretion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Opioid
Description: Opioids will be administered as standard of care for osteoarthritis (OA) pain therapy during the double-blind treatment phase as per investigator discretion.
Study: NCT03574610

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Rotating Permanent Magnet Stimulator (TRPMS)
Description: TRPMS is a wearable non-invasive transcranial rotating permanent magnet stimulator. It has been determined to be a Non Significant Risk device by the FDA.~The amount and frequency of therapy are prescribed by the physician, and the device is custom configured to the patient to deliver the required amount of treatment. The device does not turn on until it is time for the treatment. It consists of three main parts: Neoprene cap with microstimulator(s), stimulator console (device controller box) and the tablet with TRPMS app which activates the console. The neoprene cap prevents the microstimulator(s) from coming in direct contact with the scalp. Microstimulators deliver the magnetic stimulation to the brain based on a prescription program uploaded in the stimulator controller.